Crestor reduced LDL-C by more than 50% at a low 10mg dose

05/26/2004

We would like to take this opportunity to update you on some recent milestones for out statin CRESTOR (rosuvastatin calcium). CRESTOR was launched in the US in September 2003 as an adjunct to diet to reduce elevated cholesterol, low-density lipoprotein cholesterol, triglycerides, and other atherohenic lipid measures and to increase high-density lipoprotein cholesterol in patients with dyslipidemia. Worldwide, more than 1 million patients have been treated with CRESTOR, with over 2 million prescriptions dispensed. The most recent safety revire of CRESTOR has just been completed and was submitted on March 4, 2004, to the FDA. A review of this data by AstraZeneca internal drug safety concluded that the safety profile od CRESTOR was found to be consistent with our original FDA-approved label. The overall safety profile of CRESTOR is consistent with that of other marketed statins. In addition, CRESTOR continues to demonstrate an impressive efficacy profile.

As you may already know:

The safety and eddicacy of CRESTOR were evaluated in over 10,000 patients in clinical trials, more than any other statin at the time of FDA approval.

Of these patients, over 2,000 were treated for 2 years longer.

Overall, more than 40,000 patients have takes CRESTOR in clinical trials, including ongoing trials in the GALAXY Program.

CRESTOR is now approved in 51 countries and is available in pharmacies across the US.

Furthermore, in the CRESTOR clinical program:

CRESTOR reduced LDL-C by more than 50% at a low 10-mg dose ( vs 7% with placebo)

In comparisons of doese-response curves, CRESTOR reduced LDL-C significantly more than atorvastatin

CRESTOR 5 mg to 40 mg increased HDL-C between 8% and 14% (vs 3% with placebo)

The following supports the need for a product of greater LDL-C efficacy such as CRESTOR:

The National Cholesterol Education Program (NCEP) guidelines currently recommend that the goall of treatment in patients with established coronary artery disease should be an LDL cholesterol level of less than 100mg per deciliter.

Recent and emerging data from clinical trials such as PROVE-IT and the ALLIANCE Trials demonstrate that patients benefited from early and continued lowering of LDL cholesterol to levels substantially below current larger levels.

As you counsel your customers who have been prescribed CRESTOR (rosuvastatin calcium), we want you to be completely informed of the facts. The facts for CRESTOR are reflected in the prescribing information for this product and are fully supported by substantial postmarketing experience. These facts clearly indicate that CRESTOR is an excellent first-line option for a wide range of adult patients with dyslipidemia. You can feel confident in the knowledge that AstraZeneca maintains a thorough pharmacovigilence program, anad we are committed to accurately reporting the safety profile of all of our products.

Thank you for your continued interest in, and support of, CRESTOR. If you have any additional questions concerning CRESTOR, please refer to the prescribing information for CRESTOR or call the AstraZeneca Information center at 1-800-236-9933. Further information is also available at www.astrazeneca-us.com and www.crestor.com.

Source: AstraZeneca

back to front page

From: WellPoint NextRx

July 13, 2006

Important Notice: Please share this information with all Pharmacists on your Staff

Effective August 15, 2006, Wellpoint NextRx, is pleased to introduce its newest client, HealthSytems. HealthSystems represents more than 1.1 million eligible members nationwide. Reimburstment will be in accordance with the WellPoint NextRx network rate. For your convenience, all HealthSystems' processing information is listed on the attached payer sheet. This program will require a new payer setup, including a unique BIN number in your Pharmacy system for appropriate transaction routing / processing. Please route the payer sheet to the appropriate individual for setup in your system at your earliest convinience.

Members will be presenting a prescription card or a representative from HealthSystems will be contactting you if one of their members will be utilizing your Pharmacy. They will provide guidance on how to submit a claim and will be providing you with additional information about the program.

Please note the following important information. HealthSystems will be responsible for all claims processing, customer service questions, and payment to Pharmacies.

All claims should be submitted to BIN # 012874 (unique for this client)

All Pharmacy service calls should be reffered to 800-758-5779

If you should have any questions that are not related to claims transmittal details for HealthSystems, please contact WellPoint NextRx network department at 800-230-8635, option 1.

Sincerely,

Keith A. Dostal, RPh Staff V.P. Pharmacy Provider Networks WellPoint NextRx

Wellpoint NextRx is a service mark of WellPoint, Inc. Services are provided by a WellPoint PBM (either Professional Claim Services Inc. doig business as WellPoint Pharmacy Management, or Anthem Prescription Management, LLC, as appropriate).